0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Minerva Neurosciences Inc

Healthcare US NERV

2.43USD
-0.09(3.57%)

Last update at 2024-04-25T20:00:00Z

Day Range

2.432.50
LowHigh

52 Week Range

1.2613.22
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -32.10868M -51.70931M 1.94M -74.43700M -50.17129M
Minority interest - - - - -
Net income -38.98603M -49.90595M 1.94M -72.18300M -50.17129M
Selling general administrative 10.58M 13.33M 17.29M 17.74M 16.84M
Selling and marketing expenses - - - - -
Gross profit - - 41.18M - 0.00000M
Reconciled depreciation 0.00851M 0.10M 0.18M 0.16M 0.02M
Ebit -25.23133M -45.36566M 1.85M -75.86510M -51.72988M
Ebitda -25.22281M -45.26387M 1.93M -75.86400M -51.71242M
Depreciation and amortization 0.00851M 0.10M 0.08M 0.00110M 0.02M
Non operating income net other - - 0.09M 1.43M 1.67M
Operating income -25.23133M -45.36566M 1.85M -75.86510M -51.72988M
Other operating expenses 25.23M 45.37M 39.33M 75.86M 51.73M
Interest expense 7.41M 6.33M 0.00000M 1.59M 0.11M
Tax provision 0.00000M -1.80336M 0.00000M -2.25413M 0.00000M
Interest income - - - 1.43M 1.67M
Net interest income -7.40655M -6.32732M - 0.00000M -0.11045M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 6.88M -1.80336M -0.09402M -2.25400M 1.67M
Total revenue 0.00000M 0.00000M 41.18M 0.00000M 0.00000M
Total operating expenses 25.23M 45.37M 39.33M 75.86M 51.73M
Cost of revenue - - - - 0.00000M
Total other income expense net -6.87735M -6.34365M 0.09M 1.43M 1.67M
Discontinued operations - - - - -
Net income from continuing ops -32.10868M -49.90595M 1.94M -72.18349M -50.17129M
Net income applicable to common shares -32.10868M -49.90595M 1.94M -72.18349M -50.17129M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 55.09M 77.12M 57.63M 77.50M 139.14M
Intangible assets 0.04M 0.05M 15.20M 15.20M 34.20M
Earning assets - - - - -
Other current assets 3.97M 1446.36M 2083.26M 1282.48M 2.02M
Total liab 75.11M 69.15M 4.96M 49.72M 48.87M
Total stockholder equity -20.02422M 7.98M 52.66M 27.78M 90.26M
Deferred long term liab - - 1.80M 1.80M 4.06M
Other current liab 0.41M 0.97M 2.05M -41171.46100M 1.81M
Common stock 0.00053M 0.00427M 0.00427M 0.00400M 0.00389M
Capital stock 0.00053M 0.00427M 0.00427M 0.00391M 0.00389M
Retained earnings -366.81007M -334.70140M -284.79545M -286.73600M -214.55273M
Other liab 73.73M 66.33M 1.80M 42.98M 45.26M
Good will 14.87M 14.87M 14.87M 14.87M 14.87M
Other assets - 1.50M 15.32M 15.21M 34.21M
Cash 36.09M 60.76M 25.36M 21.41M 50.23M
Cash and equivalents - - - - -
Total current liabilities 1.38M 2.82M 3.16M 6.63M 3.61M
Current deferred revenue - - - 41175.60M 41175.60M
Net debt -36.09361M -60.75508M -25.24572M -21.12900M -50.23487M
Short term debt - - 0.11M 0.17M -41175.60000M
Short long term debt - - - - -
Short long term debt total - - 0.11M 0.28M -
Other stockholder equity 346.79M 342.67M 337.45M 314.51M 304.81M
Property plant equipment 0.02M - 0.10M 0.02M 0.03M
Total current assets 40.16M 62.20M 27.44M 47.14M 90.02M
Long term investments - - - - 0.00000M
Net tangible assets -34.93619M -6.94484M 22.59M -2.28986M 41.20M
Short term investments - - 0.00000M 24.44M 37.76M
Net receivables 3.12M - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.97M 1.85M 1.00M 2.32M 1.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - 0.00427M 0.00391M 0.00389M
Preferred stock total equity - - - - -
Retained earnings total equity - - -284.79545M -286.73622M -214.55273M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M - 0.01M 0.01M 0.01M
Deferred long term asset charges - - - - -
Non current assets total 14.93M 14.92M 30.19M 30.36M 49.12M
Capital lease obligations - 0.00000M 0.11M 0.28M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01633M 0.00000M 24.53M 14.08M 69.49M
Change to liabilities -0.88355M 0.86M -44.58274M 2.85M 0.73M
Total cashflows from investing activities -0.01633M -0.01633M 24.53M 14.08M 69.49M
Net borrowings - - - - -4.00070M
Total cash from financing activities -0.00001M 60.00M 13.24M 0.52M -3.34477M
Change to operating activities -3.17681M -0.59827M -3.05944M 2.92M -0.25307M
Net income -32.10868M -49.90595M 1.94M -72.18349M -50.17129M
Change in cash -24.66147M 35.40M 3.94M -28.82225M 24.20M
Begin period cash flow 60.86M 25.46M 21.51M 50.33M 26.13M
End period cash flow 36.19M 60.86M 25.46M 21.51M 50.33M
Total cash from operating activities -24.64514M -24.60187M -33.82202M -43.43222M -41.94176M
Issuance of capital stock - 0.00000M 12.55M - 0.00000M
Depreciation 0.00851M 0.10M 0.18M 0.16M 0.02M
Other cashflows from investing activities - - - 14.08M 69.49M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 13.24M 0.52M 0.66M
Other cashflows from financing activities -0.00001M 60.00M 0.69M 0.52M 0.66M
Change to netincome 11.52M 24.94M 9.70M 25.92M 8.18M
Capital expenditures 0.02M 0.02M 0.02M 0.02M 0.00000M
Change receivables - - - - -
Cash flows other operating - - -0.97368M 0.59M -0.62187M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 3.94M -28.82225M 24.20M
Change in working capital -4.06035M 0.26M -45.55643M 3.43M 0.11M
Stock based compensation 4.11M 5.22M 9.70M 9.17M 8.18M
Other non cash items 1810.76M 21.53M -0.08677M 18.24M 0.04M
Free cash flow -24.66147M -24.60187M -33.82202M -43.43222M -41.94176M

Fundamentals

  • Previous Close 2.52
  • Market Cap47.83M
  • Volume5769
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-26.33269M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -16.83895M
  • Diluted EPS TTM-4.67

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NERV
Minerva Neurosciences Inc		 -0.09 3.57% 2.43 - 11.21 1.87 2.68 0.03 0.04
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Minerva Neurosciences Inc

1601 Trapelo Road, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Dr. Remy Luthringer Ph.D. Exec. Chairman & CEO 1961
Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA Pres 1961
Mr. Frederick W. Ahlholm CPA, CPA Sr. VP, CFO & Sec. 1966
Prof. Michael Davidson M.D. Chief Medical Officer 1950
Mr. Joseph Reilly Sr. VP & COO 1975
Mr. William B. Boni VP of Investor Relations & Corp. Communications 1952
Dr. Ramana Kuchibhatla Ph.D. Sr. VP and Head of R&D NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).